The Metagenomic Sequencing Market is anticipated to reach USD 1.73 Billion by 2032 at 15.5% CAGR during the forecast period 2023-2032
The Metagenomic Sequencing Market is experiencing significant growth as researchers and scientists increasingly turn to advanced DNA sequencing techniques to explore complex microbial communities. Metagenomic sequencing involves the analysis of genetic material directly obtained from environmental samples, allowing for the comprehensive study of microbial diversity and function.
DNA sequencing techniques play a pivotal role in metagenomics, enabling the identification and characterization of microorganisms within a given sample. High-throughput sequencing technologies, such as next-generation sequencing (NGS), have revolutionized metagenomic studies by providing faster and more cost-effective methods for analyzing large-scale genomic data.
One of the key driving factors behind the expansion of the Metagenomic Sequencing Market is the growing interest in understanding the meta genome – the collective genetic material of a microbial community. Meta genomics goes beyond traditional single-species genomic analysis, offering insights into the interactions and dynamics of entire microbial ecosystems. This is particularly valuable in fields such as environmental microbiology, agriculture, and healthcare.
The demand for metagenomic sequencing services is also fueled by its applications in various industries, including pharmaceuticals, biotechnology, and environmental monitoring. Researchers leverage meta genomic data to discover novel genes, understand microbial functions, and explore potential applications in fields like bioenergy production and bioremediation.
Major Key Players:
Global Metagenomic Sequencing Companies include Enterome Bioscience (France), GATC Biotech AG (Germany), Aperiomics, Inc. (U.S.), Illumina Inc. (U.S.), The Mitre Corporation (U.S.), F Hoffman-La Roche Ltd. (Switzerland), Second Genome Therapeutics (U.S.), SciGenom Labs Pvt. Ltd. (India), Quest Diagnostics Incorporated (U.S.), GenapSys, Inc. (U.S.), Freenome Inc. (U.S.), COSMOSID (U.S.), Beijing Genomics Institute (China), Pacific Biosciences (U.S.), Biomatters Ltd. (New Zealand), Oxford Nanopore Technologies Inc. (UK), Thermo Fisher Scientific Inc. (U.S.), CLC Bio (Qiagen) (Denmark), DNAStar Inc. (U.S.), Agilent Technologies Inc. (U.S.), Macrogen Inc. (South Korea), Knome Inc. (U.S.), and Helicos BioSciences (U.S.) among others.
Segment Analysis
MRFR has segmented the report into four key dynamics for an easy grasp;
By Technology: Sequencing and Bioinformatics among others.
By Application : Infectious Disease Diagnosis, Environmental Remediation, Gut Microbe Characterization, Biotechnology, Biofuel, Ecology, and Agriculture among others.
By End-user : Hospitals, Research Institutes, and Specialized Clinics among others.
By Regions : North America, Europe, Asia Pacific, and the Rest-of-the-World (RoW).
Regional Analysis
The North American region leads the global metagenomic sequencing market owing to the presence of global players who are focused on introducing the procedures with innovative technology. Encouraging governmental support for R&D activities in healthcare and metagenomic sequencing tests is acting as a significant tailwind that is pushing up the market.
Additional factors encouraging the growth of the market include increased uptake of advanced technologies in the next generation sequencing procedures and its increasing applications and high healthcare expenditures.
The metagenomic sequencing market in the US backed the increasing demand for metagenomic sequencing, contributes to the growth of the regional market majorly. Heading with the rising demands for metagenomic sequencing procedures, the region will create a larger revenue pocket in the global metagenomic sequencing market by 2023.
Heading with the significant advancements of technologies and their wide uptake in the medical sector, the metagenomic sequencing market in the European region holds the second position in terms of size.
Moreover, the presence of a flourishing medical devices market and rising healthcare expenditure in the region will facilitate the growth of the market. Also, factors such as support and funding from public & private sectors for research & development impacts the market growth in the region positively.
Furthermore, the availability of low-cost metagenomic and NGS procedures and their rising adoption by research laboratories are driving the growth of this market.
The Asia Pacific region heading with the increasing prevalence of genetic disorders has emerged as a promising market for metagenomic sequencing. The large unmet clinical needs are attracting the foreign investors and global players to focus on this region to expand the network that is helping them to capture major share of the market.
Browse Related Reports:
For More Information, Please Visit @ Market Research Future
Chinese
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek